Bifidobacterium longum subsp infantis (EVC001) is associated with reduced incidence of necrotizing enterocolitis stage ≥2 and bloody stools in premature babies.

IF 2.4 3区医学 Q2 OBSTETRICS & GYNECOLOGY

Journal of Perinatology Pub Date : 2024-12-06 DOI:10.1038/s41372-024-02188-8

Kristin Sohn, Victoria Palacios, Reese Clark

{"title":"Bifidobacterium longum subsp infantis (EVC001) is associated with reduced incidence of necrotizing enterocolitis stage ≥2 and bloody stools in premature babies.","authors":"Kristin Sohn, Victoria Palacios, Reese Clark","doi":"10.1038/s41372-024-02188-8","DOIUrl":null,"url":null,"abstract":"Objective: To utilize an evidence-based probiotic protocol to achieve a 50% reduction in necrotizing enterocolitis (NEC) ≥ stage 2 and bloody stools.Study design: From January 2022 through September 2023, daily enteral Bifidobacterium longum ssp. infantis EVC001 (B. infantis EVC001) was administered to babies ≤ 33 6/7 weeks gestation until 36 weeks post menstrual age. Feeding tolerance and complications were compared to babies admitted during the prior two-year period. Fisher's Exact test was used to analyze proportional data and t test was used for continuous variables.Results: A total of 265 babies received EVC001, and a total of 277 babies formed the pre-probiotic cohort. Probiotic use was associated with decreased NEC ≥ stage 2 (p = 0.0058), reduced bloody stools (p < 0.0001), decreased time to full enteral feeds (p < 0.0001), and decreased total parenteral nutrition (TPN) days (p < 0.0001).Conclusion: Administration of B. infantis EVC001 was associated with a decrease in NEC, a decrease in bloody stools, and improvement in feeding tolerance in premature babies.","PeriodicalId":16690,"journal":{"name":"Journal of Perinatology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41372-024-02188-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To utilize an evidence-based probiotic protocol to achieve a 50% reduction in necrotizing enterocolitis (NEC) ≥ stage 2 and bloody stools.

Study design: From January 2022 through September 2023, daily enteral Bifidobacterium longum ssp. infantis EVC001 (B. infantis EVC001) was administered to babies ≤ 33 6/7 weeks gestation until 36 weeks post menstrual age. Feeding tolerance and complications were compared to babies admitted during the prior two-year period. Fisher's Exact test was used to analyze proportional data and t test was used for continuous variables.

Results: A total of 265 babies received EVC001, and a total of 277 babies formed the pre-probiotic cohort. Probiotic use was associated with decreased NEC ≥ stage 2 (p = 0.0058), reduced bloody stools (p < 0.0001), decreased time to full enteral feeds (p < 0.0001), and decreased total parenteral nutrition (TPN) days (p < 0.0001).

Conclusion: Administration of B. infantis EVC001 was associated with a decrease in NEC, a decrease in bloody stools, and improvement in feeding tolerance in premature babies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Perinatology 医学-妇产科学

CiteScore

5.40

自引率

6.90%

发文量

284

审稿时长

3-8 weeks

期刊介绍： The Journal of Perinatology provides members of the perinatal/neonatal healthcare team with original information pertinent to improving maternal/fetal and neonatal care. We publish peer-reviewed clinical research articles, state-of-the art reviews, comments, quality improvement reports, and letters to the editor. Articles published in the Journal of Perinatology embrace the full scope of the specialty, including clinical, professional, political, administrative and educational aspects. The Journal also explores legal and ethical issues, neonatal technology and product development. The Journal’s audience includes all those that participate in perinatal/neonatal care, including, but not limited to neonatologists, perinatologists, perinatal epidemiologists, pediatricians and pediatric subspecialists, surgeons, neonatal and perinatal nurses, respiratory therapists, pharmacists, social workers, dieticians, speech and hearing experts, other allied health professionals, as well as subspecialists who participate in patient care including radiologists, laboratory medicine and pathologists.